Government ❯ Regulation ❯ FDA

Drug Approval

Mifepristone Biologics License Application Compounding Pharmacies Patient Safety Safety Communications Psychedelic Drug Mifepristone Approval Public Health Safety New Drug Application NDA Clinical Trials Public Health Policy Labeling Changes Agricultural Products Animal Health Solutions Sunscreen Ingredients Wegovy Pill Compounded Medications Peptide Reclassification Exdensur Telehealth Public Health Vaccine Approval Process Breakthrough Therapy Designation Marketing Violations Environmental Impact Studies Advertising Standards Psychedelic Medications Healthcare Policies Compounding Regulations Peptide Regulation Sunscreen Regulation OTC Monograph Synthetic Drugs Peptide Compounding Clinical Evidence mFLUSIVA

Capricor Hit with Multiple Investor Lawsuits After FDA Questions Unagreed Trial Analysis

Investor groups are racing to seek lead‑plaintiff status following the FDA’s decision to extend its review of deramiocel to November 22, 2026.

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

FDA Advisers Recommend BPC-157 for Pharmacy Compounding

Atara Faces Investor Class Action Over FDA Rejections of EBVALLO

Class Action Filed Against Atara Biotherapeutics Over Alleged Misstatements on FDA Setbacks

FDA Warns ImmunityBio Over Anktiva Ads, Citing Misleading Cancer Claims

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

FDA Proposes Adding Bemotrizinol to U.S. Sunscreens, Invites Public Comment

FDA Grants Conditional Approval to Exzolt Cattle-CA1 for Screwworm and Cattle Fever Tick

FDA Investigates Fatal Liver Failures Linked to Sarepta’s Elevidys Therapy

Democratic-Led States Petition FDA to Remove Mifepristone Restrictions